Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Calidi Biotherapeutics Inc’s stock clocked out at $0.59, down -0.92% from its previous closing price of $0.6. In other words, the price has decreased by -$0.92 from its previous closing price. On the day, 1.82 million shares were traded.
Ratios:
To gain a deeper understanding of CLDI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.12 and its Current Ratio is at 2.12. In the meantime, Its Debt-to-Equity ratio is 0.68 whereas as Long-Term Debt/Eq ratio is at 0.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on November 22, 2023, initiated with a Buy rating and assigned the stock a target price of $11.
On October 09, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $9.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 17 ’24 when Camaisa Allan sold 10,000 shares for $1.62 per share. The transaction valued at 16,200 led to the insider holds 66,712 shares of the business.
Stock Price History:
Over the past 52 weeks, CLDI has reached a high of $3.89, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is 32.83%, while the 200-Day Moving Average is calculated to be -36.49%.
Shares Statistics:
A total of 34.52M shares are outstanding, with a floating share count of 32.31M. Insiders hold about 6.52% of the company’s shares, while institutions hold 15.75% stake in the company.
